The Oncologist, Vol. 11, No. 5, 531-532, May 2006; doi:10.1634/theoncologist.11-5-531
© 2006 AlphaMed Press
In Reply
Deborah K. Armstrong
Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, USA
Correspondence:
Deborah K. Armstrong, M.D., The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, Room 190, 1650 Orleans Street, Baltimore, Maryland 21231, USA. Telephone: 410-614-2743; Fax: 410-955-0125; e-mail: darmstro{at}jhmi.edu
Received March 10, 2006;
accepted for publication April 3, 2006.
I appreciate the letter and information from Dr. Muggia [1]. As he notes, their group has a long history studying the use of topotecan as a continuous infusion in the treatment of ovarian cancer. In the past, the requirement for cumbersome infusion devices made this a less appealing approach. However, as indicated, advances in biotechnology allow for easier infusion using this approach, which continues to be under investigation. Of note, an oral formulation of topotecan is currently under investigation [2, 3]. It is hypothesized that continuous oral dosing of topotecan may have similar pharmacokinetics to and possibly the beneficial antitumor effects of continuous infusion i.v. topotecan. This remains an active area of investigation.
 |
DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST
|
|---|
The author indicates no potential conflicts of interest.
|
REFERENCES
|
|---|
- Muggia F, Kosloff R, Liebes L et al. Topotecan Continuous Infusion: CA-125 Responses Including Patients Pretreated with Other Schedules of Topotecan. The Oncologist 2006;11:529–531.[Free Full Text]
- Rose PG, Markman M, Bell JG et al. Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study. Gynecol Oncol 2006 Jan 10; [Epub ahead of print].
- Gore M, Oza A, Rustin G et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer 2002;38:57–63.[Medline]
Top
Disclosure of Potential...
References
